Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial

AIM: To evaluate the efficacy and safety of insulin glargine 300 U/mL (Gla‐300) versus insulin degludec 100 U/mL (IDeg‐100) in predefined (</≥65 years) and post hoc (</≥70 years) age groups of people with type 2 diabetes (T2D) in the BRIGHT trial. MATERIALS AND METHODS: BRIGHT was the first he...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Obes Metab
Hlavní autoři: Bolli, Geremia B., Cheng, Alice, Charbonnel, Bernard, Aroda, Vanita R., Westerbacka, Jukka, Bosnyak, Zsolt, Boëlle‐Le Corfec, Emmanuelle, Rosenstock, Julio
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2021
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8252805/
https://ncbi.nlm.nih.gov/pubmed/33687748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14372
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky